C

Celyad Oncology
CYAD

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
€19.89M
EV
€16.59M
Shares Outstanding
41.89M
Beta
1.24

Wall Street View

Analyst Rating
NOT_AVAILABLE
Analyst Target Price
-
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Celyad Oncology SA

gainify

C

Celyad Oncology SA

CYAD

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of ...

Sector

Healthcare

Industry

Biotechnology

CEO

Kane, Matthew

Employees

18

IPO Date

2013-07-04

Headquarters

Axis Business Park, Rue AndrE Dumont 9, Mont-Saint-Guibert, Walloon Brabant, 1435, Belgium

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved